Antibiotic testing in shrimp

Home - Archives for April 2019

Antibiotic testing in shrimp

Seafood is one of the most important exports in India with its shrimp being a staple food in many countries worldwide. However, 2017 and 2018 saw 27 shipments of shrimp refused entry into the US by the FDA. This was followed closely in January 2019, when 26 lines were refused due to the presence of two banned antibiotics, nitrofurans and chloramphenicol.

With Indian shrimp accounting for around one third of the countries seafood exports, India has expressed its concern over the rejections. It responded by calling the tests on the products ‘too stringent’.

The global shrimp industry is estimated to be worth around $30 billion and India’s market share is estimated at 13% in value terms.

Dr. Ramraj, President of the All Indian Shrimp Hatcheries Association has stated, “some of the metabolites in shrimp and crustacean shells are known to mimic antibiotics and therefore could give false results”.

The use of antibiotics in shrimp farming in India is banned. Madhusudano Rao, Principal scientist at India’s Central Institute of Fisheries Technology has said, “All shrimp hatchery operators and shrimp farmers and advised to use only these antibiotic- free inputs during shrimp farming”.

Randox Food Diagnostics offer the most comprehensive range of ELISA and Biochip tests currently on the market, specifically designed to identify and detect the smallest traces of the most prevalent antibiotics used in seafood, including nitrofurans and chloramphenicol.

For more information please email us at: info@randoxfooddiagnostics.com or visit our website at www.randoxfooddiagnostics.com.

 

 

 

 

 

 

 

 

 

 


We Are Randox | Team Randox abseils Belfast Castle for AWARE NI

On Sunday 14th April 2019, a team of brave Randox colleagues faced their fears and took part in an abseil from the top of Belfast Castle. Scaling the heights of Cavehill, our fourteen daring Randox thrill seekers enjoyed views over Belfast before they stepped over the edge.

The event took place to raise funds for Randox’s charity partner AWARE NI, the depression and bipolar charity of Northern Ireland.

Congratulations to our abseil participants! While this may be something else ticked off the ‘bucket list’, it also, most importantly, is a fantastic effort in raising awareness and funds for the work of this very worthwhile cause.

Well done to everyone with your fundraising. You have all worked very hard and raised a fantastic amount both in cash donations and via JustGiving –  around £2200 so far and counting!

We hope you enjoy the photographs from the day. If you would still like to donate, please visit: https://www.justgiving.com/teams/randox-aware-belfast-castle

Once again, many thanks on behalf of both Randox and AWARE NI to the Randox abseilers for their enthusiasm and fundraising efforts on behalf of both Randox and AWARE NI.

For more information about the abseil or our charity partnership with AWARE NI, please contact RandoxPR@randox.com.


Molecular Testing on the Evidence Investigator

The Evidence Investigator is a compact, semi-automated benchtop analyser which is renowned for its versatility, robustness and effective reporting methods. The Evidence Investigator has offered efficient and comprehensive testing in a wide range of laboratory settings for many years including, clinical diagnostics, molecular, research, toxicology and food diagnostics.

The Evidence Investigator is the perfect fit for medium throughput laboratories seeking maximum use of bench space and can process up to 44 results from a single sample, with a maximum throughput of up to 2376 tests per hour.

It is extremely well equipped to provide reliable and accurate results because results are generated using Charge Coupled Device (CCD) camera, which quantifies chemiluminescent light. The light then measures the degree of binding between the sample and specific biochip bound ligands. The Evidence Investigator image processing software translates light signal generated from chemiluminescent reactions into analyte concentrations which removes the need for any manual processing of data.

Our molecular product range offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infection (STI), respiratory tract infection, colorectal cancer, familial hypercholesterolemia (FH) and cardiovascular disease (CVD). Additionally, we can provide a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. The technology allows simultaneous detection of multiple analytes from a single sample for efficient and cost-effective testing.

Pathogen Detection

STI and Respiratory Arrays

Sexually transmitted infections (STIs) affect more than 1 million people every day and each year 500 million new cases of STIs occur.1 Therefore, it is vital for early and accurate detection. Randox’s Sexually Transmitted Infections Multiplex Array simultaneously detects 10 bacterial, viral and protozoan including primary, secondary and asymptomatic co-infection for a complete infection profile. The assay is based on a combination of multiplex PCR and biochip array hybridisation. Innovative PCR priming technology permits high discrimination between multiple targets.

Respiratory tract infections are caused by many viral and bacterial pathogens and are the second most common cause of morbidity and mortality worldwide.2 The Respiratory Multiplex Array is the most comprehensive screening test for infections of both the upper and lower respiratory tracts, simultaneously detecting 22 bacterial and viral pathogens from a single sputum lavage or nasopharyngeal sample.

Both arrays detect the most common and frequently requested infections in sexual and respiratory health. These comprehensive, highly sensitive and specific tests enable identification of co-infections simultaneously, often in asymptomatic patients and enable antibiotic stewardship.

Mutation Detection

KRAS, BRAF, PIK3CA Array and Familial Hypercholesterolemia Arrays I & II

The colorectal cancer (CRC) is the third most common cancer worldwide. Overall, the lifetime risk of developing colorectal cancer is: about 1 in 22 (4.49%) for men and 1 in 24 (4.15%) for women.3 The KRAS, BRAF, PIK3CA Array simultaneously detects 20 point mutations within the KRAS, BRAF and PIK3CA genes. The assay is validated for use with the DNA extracted from fresh/frozen and formalin fixed paraffin embedded tissue. The array is CE marked for routine clinical use.

Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism. 4It is the most common autosomal dominant, or inherited disease and affects the plasma clearance of LDL-cholesterol, resulting in premature onset of cardiovascular disease and higher mortality risk.5 Early diagnosis is crucial as by the time the FH sufferer enters early adulthood they will have accumulated >20 years of continuous exposure to build up of fatty or lipid masses in the arterial walls and are at the hundred-fold greater risk of a heart attack than other young people. The Familial Hypercholesterolemia (FH) Arrays I & II are rapid, simple and accurate detection of 40 FH-causing mutations within the LDLR ApoB and PCSK9 genes.

These unique biochip assays permit high discrimination between multiple targets in several genes with a rapid turnaround time (3 hours). The arrays enable detection of the most frequently occurring mutations known to cause disease (FH) and adversely affect patient treatment (KRAS, BRAF, PIK3CA).  A unique primer set is designed for each target which will hybridise to a complimentary oligo-nucleotide probe spotted on a biochip discrete test region (DTR).

SNP Genotyping

Cardiovascular Risk Prediction Array

Coronary Heart Disease is the leading cause of death in the developed world and its prevention is a core activity for public health systems worldwide.6 Randox have the Cardiac Risk Prediction Array which will allow for 19 SNPs to be genotyped simultaneously, which incorporate a test to identify patients predisposed to statin-induced myopathy.

This array identifies individuals with a genetic predisposition to coronary heart disease (CHD). The innovative multiplex primers are designed to discriminate DNA sequences which differ only at one base.

For more information on our Evidence Series or Molecular range of Assays, contact us at info@biosciencesrandox.com

  1. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
  2. https://www.ncbi.nlm.nih.gov/pubmed/25189349
  3. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472364/
  5. https://www.ncbi.nlm.nih.gov/books/NBK395572/
  6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864143/

 

 

 

 

 

 

 

 

 


Kratom: The Emerging Drug of Abuse

Amidst growing concerns of an opioid-abuse epidemic in the United States, it has been established that kratom (Mitragynine) is increasing in popularity amongst opioid users and has been reported as the new ‘legal high’.

Kratom is an unendorsed herb substance which has not yet been criminalized in the United States and is considered a powerful analgesic with opioid-like effects at high doses and acts as a stimulant at lower doses. Often used as a treatment for chronic pain or opiate withdrawal patients, it also comes in the form of a dietary supplement. As there are no Federal regulations monitoring the sale and distribution of Kratom the substance continues to be readily available and easily accessible via the internet, increasing its abuse by chronic pain patients on prescription opioids.

Kratom has been associated with psychosis, seizures, and has recently cited 100 deaths over a 17-month period by the Centers for Disease Control and Prevention (CDC). In previous reports, the Food and Drug Administration had warned against the use of Kratom to ease opioid withdrawal, as many pain physicians are not familiar about its addictive properties. Further the DEA plans to classify kratom as a Schedule 1 substance.

Are you testing for Kratom?

Randox Toxicology are the only suppliers for the detection of Kratom. Alongside our exclusive highly sensitive kratom ELISA test, this drug of abuse is available on our New Psychoactive Substances II panel, which utilises our universally available patented Biochip Array Technology.

Offering excellent cross-reactivity and unrivalled limits of detection over a range of routine and novel assays Biochip Array Technology is the world’s first multiplex screening technology. Designed to work across multiple matrices such as urine, blood, and oral fluid its intra and inter assay precision is typically <10% giving excellent correlation with confirmatory methods.

For more information regarding our Kratom tests get in touch with us by emailing info@randoxtoxicology.com

 

 

 

 

 

 

 

 


Improving stroke diagnoses with Randox Biosciences

A stroke can happen to anyone at any time. It is a serious life-threatening medical condition which occurs when the blood supply to part of the brain is cut off. It causes the brain cells to die resulting the abilities controlled by the brain such as memory and muscle control to become damaged. 1

According to the Stroke Association, strokes are considered the fourth biggest killer in the UK. There are more than 100,000 strokes each year which equals around one stroke every five minutes.2 Some people recover from the condition; however, two thirds of the survivors will have some sort of disability. 3

There are two mains types of strokes which are defined as “Ischemic strokes” and “Hemorrhagic stroke”.

Ischemic Stroke

Ischemic stroke is by far the most common kind of stroke, accounting for about 88% of all cases4. Ischemic strokes occur when there is an artery blockage which cuts off the blood supply to certain areas of the brain, which then results in brain cells being unable to make energy and dying. The arteries are vital for the brain as they bring fresh blood from the heart and lungs carrying oxygen and nutrients and taking away carbon dioxide and cellular waste. 4

Hemorrhagic Stroke

The hemorrhagic stroke is less common but is more severe as there is a higher risk of dying within the first three months. It is when a blood vessel ruptures causing a bleed inside the brain, resulting in the death of brain cells. They are responsible for 40% of all stroke deaths.5

Symptoms of Stroke

The most commons symptoms of a stroke are:

  • Weakness or numbness of the face, arm, or leg on one side of the body
  • Loss of vision or dimming in one or both eyes
  • Loss of speech, difficulty talking, or understanding what others are saying
  • Sudden, severe headache with no known cause
  • Loss of balance or unstable walking, usually combined with another symptom

Many risk factors can increase your chance of having a stroke. Some life style factors include being obese/overweight, not exercising enough, heavy drinking, use of illegal drug such as cocaine, cigarette smoking, high cholesterol, diabetes, disruptive sleeping pattern and family history of having stroke or heart attack.

Preventing Stroke

Up to 80% of strokes are preventable. 3 There are simple healthy lifestyle recommendations that could decrease your chances of developing a stroke in the future which include:

  • Controlling your blood pressures as it is one of the biggest preventions of developing a stroke.
  • Maintaining a healthy weight through a well-balanced diet involving rich fruit and vegetables as well as decreasing the amount of cholesterol, saturated fat and sodium intake.
  • Exercising regularly and staying within a good routine will also reduce your risk of having a stroke.
  • Quitting tobacco usage and decreasing alohcal intake will help as well as regular usage increases the risk of having high blood pressure.
  • Avoid taking illegal drugs such as cocaine as it reduces your blood flow which narrows the arteries.

Randox Biosciences offers a stroke array which works quickly to determine which type of stroke a person has experienced. Ischaemic stroke can be treated by thrombolysis and, with early usage, it can help limit stroke damage and disability.

However, inappropriate administration of thrombolytic therapy can cause serious adverse effects, including intracranial haemorrhage. Hence, there is an unmet clinical need for a rapid and highly sensitive testing that complements existing CT scanning approaches and facilitate the definitive identification of ischaemic stroke patients.

Randox’s innovative Biochip Array Technology enables simultaneous detection of eight stroke biomarkers from a single blood sample.

The eight biomarkers that can be detected in a single blood sample are:

  • Glutathione S-Transferase-Pi (GSTP-Pi)
  • Nucleoside Diphosphate Kinase A (NDKA)
  • Parkinson Protein 7 (PARK7)
  • Glial Fibrillary Acidic Protein (GFAP)
  • D-Dimer
  • Interleukin 6 (IL-6)
  • sNFR1
  • Heart Fatty Acid Binding Protein (H-FABP)

 

For more information email us at info@randoxbiosciences.com or visit our newly improved website: https://goo.gl/8qkYkg

 

  1. https://www.nhs.uk/conditions/stroke/
  2. https://www.stroke.org.uk/system/files/sotn_2018.pdf
  3. https://www.stroke.org/understand-stroke/what-is-stroke/stroke-facts/
  4. http://www.strokecenter.org/patients/about-stroke/ischemic-stroke/
  5. https://www.stroke.org/understand-stroke/what-is-stroke/hemorrhagic-stroke/

 

 

 

 

 

 

 

 

 

 


Photo Album: Randox Health Grand National 2019

We hope you enjoy our selection of photography from this year’s Randox Health Grand National.

From the electric atmosphere to the beautiful weather and the fact that Tiger Roll came home first for a second year, the 2019 Randox Health Grand National was an event that we will always remember.

For further information about the Randox Health Grand National, please contact the Randox PR team by emailing randoxpr@randox.com or phoning 028 9442 2413.

 

 

 

 

 

 


We Are Randox | Celine and Kenny dive into fundraising for AWARE NI

We’re passionate about celebrating the kindness and generosity of our Randox employees. Each have their own unique and interesting story to tell and many give up their spare time to support their local community and help those in need.

Their compassion and commitment is what makes Randox the successful company it is today, and this month we have two Randox employees whose bravery and dedication emulates this perfectly.

Céline Hasson, Randox Customer Relationship Executive, and Kenny Galloway, Business Relations Manager are both taking to the skies on Saturday 18th May for a charity skydive in aid of one of our official charity partners, AWARE NI.

Below they both explain why they wanted to take part in the charity skydive, and what it means to them to be able to raise funds for the main depression charity for Northern Ireland.

Kenneth Galloway, Randox Health Business Relations Manager, commented;

“This year in 2019 so far we have already seen so many people take their own lives here in Northern Ireland. It’s so terribly heartbreaking and let’s face it, avoidable. Our help is needed more than ever which is why I have decided to conquer my fear of heights and hurl myself out of an airplane at 10,000 feet. I want to be able to raise awareness of this charity and to raise money to allow other people to benefit from what could be, to many, a life-changing service.

“Together we can make a difference, so I humbly ask you today to be a part of this great cause, by making a donation big or small.”

Céline Hasson, Customer Relationship Executive, added;

“People with mental health conditions deserve as much support and compassion as those will physical health conditions. So with this in mind I have signed myself up for a skydive in May with a goal to fundraise £500+ for AWARE NI.

“I’m sure every person reading this has either suffered or knows someone who has/is suffering from depression, so please donate to a great cause like AWARE NI. Let’s support them to help support others.”

Did you know?

  • 1 in 4 people will experience some kind of mental health problem each year
  • Anxiety and depression are the most common mental disorders
  • Overall prevalence of mental health conditions in Northern Ireland is up to 25% higher than in England
  • 9 out of 10 people with mental health problems experience stigma and discrimination

What can you do?

Whilst Céline and Kenny have committed to a skydive with Moonjumpers Sky Diving, you have the easy part.

Simply make a donation and contribute to the very worthy AWARE NI, which has an established network of 24 support groups in rural and urban areas across the county, and also delivers mental health and well-being programmes into communities, schools, colleges, universities and workplaces.

To view Kenny’s JustGiving page please visit; https://www.justgiving.com/fundraising/kenny-jnr

To view Céline’s JustGiving page please visit; https://www.justgiving.com/fundraising/celine-hasson1

For further information about Randox’s charity work with AWARE NI, please contact the Randox PR team by emailing randoxpr@randox.com or phoning 028 9442 2413.

 

 

 

 

 

 


Different methods of drug testing and the benefits of each

Types of Drug Testing

At Randox Testing Services (RTS) we provide a range of testing solutions to enable you to conduct employee testing. Our screening procedure is efficient and involves an experienced sample collection officer visiting your premises to collect samples and transport them back to our laboratories for analysis. Alternatively, we can also train a member of your staff to collect samples on site with the same degree of accuracy as an RTS collection officer. Our testing solutions ensure coverage of all types of employee testing and meet the needs of all businesses.

For-Cause Testing

For-cause drug and alcohol testing is conducted when there is suspected drug abuse or alcohol misuse in the workplace. Suspicion may arise because of the employee exerting signs of substance abuse, if an allegation has been made, if drugs or alcohol have been found within the workplace or following an accident at work.

The key benefits include;

  • Legal compliance with correct measurements being taken if an employee is suspected of being under the influence of drugs or alcohol.
  • Can deter employee misuse of drugs or alcohol due to a workplace drug and alcohol testing policy being in place.

Pre-Employment Testing

Pre-employment screening for substance abuse is an increasingly common type of workplace drug and alcohol testing. As an indicator of candidate suitability, it forms an essential part of a company’s recruitment process and helps maintain the safety of its current employee workforce and business environment.

The key benefits include,

  • Pre-employment screening is one of the easiest programmes to implement.
  • Screening applicants for use of drugs and alcohol ensures you employ the right people for your business.
  • Effective way of preventing future issues such as absenteeism and decreased productivity.
  • Pre-employment screening can help protect the integrity of a company by acting as an effective deterrent.
  • A pre-employment drug test is proved helpful to boost the repute of an organisation. The drug abusers usually stay away from applying in any firm that held a drug test at the time of employment.

Random Testing

Random testing for drugs and alcohol is a popular type of employee testing. With knowledge that a test could be conducted on anyone at any time it acts as an effective deterrent of drug abuse or alcohol misuse among employees.

The key benefits include;

  • Random testing is a deterrent for employees as they are aware they could be asked to undertake a test at any time.
  • It is a convenient and easy way to maintain a safe working environment free from substance abuse.
  • Employees are less likely to tactfully try to disguise results, or alter their habits, as they will be given little or no notice that a test is going to be conducted.
  • Employees are less likely to feel singled out due to random selection.

Post-incident testing

Post-incident testing occurs after an accident or incident in the workplace to determine if drugs or alcohol may have contributed to the cause. Incidents include injury to an employee, assault of an employee by another member of staff or damage to property.

If this is required, it is recommended that all employees involved in the incident are tested.

The key benefits include;

  • Safeguards the rights of the employees and employers to proving or disproving if drugs or alcohol were a factor in an incident.
  • Minimises the chance of a similar incident occurring.

Abstinence Monitoring

Abstinence monitoring provides employees with the support and opportunity to remain abstinent and continue to successfully at work. This type of testing is an effective tool to track progress towards addiction recovery for both the employee and the employer. Regular drug screens also give the recovering person added motivation to protect their sobriety.

For the employer abstinence monitoring provides greater security in knowing that their employee is safe to work. This is particularly important for safety critical roles.

The key benefits include;

  • Ensures that an employer is tackling and reducing the instances of substance abuse in the workplace.
  • Shows support from an employer throughout an employee’s rehabilitation process.
  • Increases employee morale and productivity.
  • Helps prevent staff turnover by offering a second chance.
  • Studies have shown that close monitoring by physicians, especially in early recovery, results in abstinence rates of over 80%.

At RTS we offer varied testing methods to be as flexible as the customer needs to fit in with their requirements.

For any further questions about implementing a workplace drug and alcohol testing policy or just general questions on workplace testing, please get in touch today!

Email – testingservices@randox.com

Phone – +44 (0) 28 9445 1011

 

 

 

 

 

 

 


Tiger Roll wins back-to-back Randox Health Grand Nationals

The sponsor of the Randox Health Grand National has congratulated Tiger Roll, Davy Russell, Gordon Elliott and Michael O’Leary as they secured their spot in the history books at Saturday’s Randox Health Grand National.

Dr. Peter FitzGerald, Managing Director of Randox Health, had high praise for both Aintree Racecourse and his Randox Health team, saying;

“We were delighted to once again partner with the Jockey Club and Aintree Racecourse, together bringing the Randox Health Grand National to the millions who avidly awaited the unfolding of this iconic event.

 “Over the last two years of our sponsorship, the theatrics that this Festival has produced have been second-to-none and this, our third year, was no exception. The atmosphere was electric and the cheers of the crowd deafening as Tiger Roll, steered by Davy Russell, stretched himself ahead of the competition to become the first consecutive winner of this most famous race since the days of Red Rum.

“It is a tale which will be forever etched in the history books of Aintree Racecourse and steeplechase racing.

“Congratulations to Tiger Roll’s jockey Davy Russell, trainer Gordon Elliott and owner Michael O’Leary who once again delivered a fairytale of determination and dedication as the small but mighty Tiger Roll stormed to victory for a second time.

 “Whilst our partnership with the Randox Health Grand National and the wider Jockey Club is an opportunity for us to spread our message of preventative health, it is also a chance to show our commitment, at a national level, to this wonderful sport. I have been a keen equestrian all my life and Randox, historically, has given its name to many local Point-to-Point and Polo meetings near our headquarters in Northern Ireland.

“It’s the perfect fit, therefore, to unite our company ethos, of helping people to extend and enjoy their lives, with the people’s race, the Randox Health Grand National. Together, we can encourage people to live healthier for longer, in order to enjoy events such as this glorious Festival for as long as possible.

 “Our message of preventative health is an important one, particularly in a health-conscious world, and that’s why we have been offering the public a 20% discount across all our health packages and services over the course of the Randox Health Grand National and until the end of April 2019.

“This year, we also highlighted our STI at-home test kit Confidante. Sexual health is a serious issue but all too often such infections are stigmatised and access to services may be problematic – causing considerable difficulties for individuals who believe they may benefit from testing. This can lead to increased health challenges at a personal level, and potentially much higher rates of infection.

Confidante allows for 10 STIs to be tested in a private and fully confidential manner, with the results provided directly to the individual.  Improving ease-of-access to such testing is an important issue to support the health needs of those who require testing of and to help reduce the overall rates of sexual infections within society.

“The Randox Health Hub at Aintree Racecourse provided race-goers with an opportunity to engage with Confidante directly through our Secret Cinema where viewers entered a private booth, unaware of the humorous short film which awaited them. Many were in good spirits as a camera caught their reactions and all were entered in to a draw to win a FitBit on each day of the Festival

 “I would like to thank the millions who joined us at the Randox Health Grand National 2019 to witness history being made – whether in person at Aintree Racecourse or tuned in to the screen or airwaves. We look forward to continuing our partnership in the coming years as we deliver the world’s most famous steeplechase and share our preventative health message.”

For more information about the Randox Health Grand National 2019 please contact the Randox PR team by emailing randoxpr@randox.com or phone 028 9442 2413.

 

 

 

 

 

 

 


Liverpool school pupils are first to lay eyes on the Randox Health Grand National 2019 trophy

School pupils across Liverpool are today enjoying an exclusive sneak-peek of the 2019 Randox Health Grand National trophy, as part of a tour hosted by Olympic Gold Medallist and Aintree ambassador Sam Quek, and acclaimed former jockey Carrie Ford.

The trophy, which has travelled to King’s Leadership Academy, Maricourt Catholic High School and Alder Hey Children’s Hospital, will be officially unveiled to the public during the Opening Ceremony of the Randox Health Grand National Festival on Thursday 4th April.

Etched in solid silver and gilded with gold, the 2019 trophy, which has been designed for the third year by Shannon O’Neill, is aptly shaped like a human antibody, to carry again the sponsor’s message of health and science which so successfully resonated with the racing fraternity in 2017 and 2018.

“We’re incredibly excited to unveil the 2019 Randox Health Grand National trophy during this year’s Opening Ceremony,” said Dr Peter FitzGerald, Managing Director of Randox Health.

“Our sponsorship of the world’s greatest race is incredibly special to us, as it is a powerful way to share our preventative health message across the globe. With its unique design, the trophy reflects the outstanding science on which Randox Health is based and the use of world class antibodies to identify disease.

“At the base of the trophy, a collection of Randox Biochips – our most innovative health testing technology – have also been brought to the fore. We’re thrilled that with each new trophy we can reflect on the scientific advances of the year gone by and share a new chapter of the Randox story.”

Those who have the opportunity to view the stunning Randox Health Grand National trophy up close, will notice small spherical structures within the stem of the festival’s most coveted prize. Alluding to proteins, one of the building blocks of the human body, this design element draws attention to an area of research in which Randox is investing significantly.

Dr FitzGerald continued; “We strongly believe that the future of healthcare lies in proteomics, the study of proteins. By utilising this innovative method of disease detection, we can identify illness within an individual before it becomes symptomatic. Proteins are released into the blood at the very earliest stage of disease development and, when they are detected, serve as the earliest warning to initiate preventive care.

“Whilst Randox leads the world in proteomic Biochips – the screening for multiple proteins at the same time – there is still much to be done. We can currently test for hundreds of different proteins at once, however, we know that there are up to 30,000 different proteins that we may wish to monitor.

“As we continue to develop diagnostic tests for these proteins, we can begin to imagine a world in which sickness is actively prevented at the earliest stage, rather than managed. In proteins lies the key to living healthier for longer.”

Another popular element returning to the presentation of the winning Randox Health Grand National prizes are team trophies. In 2017, their first year as sponsor, Randox Health introduced the concept of presenting the entire winning team with a trophy, to celebrate the combined effort that goes in to achieving such a special victory. In 2018, they went to trainer Gordon Elliott, jockey Davy Russell, and head groom Louise Dunne.

The Randox Health Grand National trophy will be available to view in the Randox Health Hub at Aintree racecourse at 11:30am and 15:30pm on each day of the Randox Health Grand National Festival.

 

 

 

 

 

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)